Diligence memo · auto-generated · as of July 2, 2026
Aria Diagnostics, Inc.
Aria Diagnostics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Aria Diagnostics, Inc. operates in Biotechnology, based in SAN JOSE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aria Diagnostics, Inc. has raised $65M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $53M on 2011-11-30.
Most recent recorded round closed around 2011-11-30.
Valuation (modeled)modeled
Provath models Aria Diagnostics, Inc. at approximately $2.2B (range $163M–$5.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.08× the median modeled value of Series C Biotechnology companies in 2010–2012 (19 peers) — value vs value, same stage and era. Within the normal band (108% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 14.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 86% of Biotechnology peers (4293 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Insmed Inc, Infinity Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Relypsa Inc, Knopp Neurosciences Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.